Holen Sie sich die Stockscreener-App
2.17
2.25%
-0.05
Schlusskurs vom Vortag:
$2.22
Offen:
$2.22
24-Stunden-Volumen:
79,900
Relative Volume:
0.46
Marktkapitalisierung:
$59.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.14M
KGV:
-2.7125
EPS:
-0.8
Netto-Cashflow:
$-12.64M
1W Leistung:
+6.37%
1M Leistung:
+19.23%
6M Leistung:
+13.02%
1J Leistung:
-67.66%
1-Tages-Spanne:
$2.09
$2.32
1-Wochen-Bereich:
$1.88
$2.44
52-Wochen-Spanne:
$1.26
$7.50
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Vergleichen Sie IMMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.17 | 59.69M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Immix Biopharma reports early success in CAR-T trial - Investing.com
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - GlobeNewswire
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 - The Bakersfield Californian
Immix Biopharma (IMMX) Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - StreetInsider.com
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 17.5% in November - MarketBeat
Immix Biopharma reports promising CAR-T therapy results - Investing.com
Terex Corp (TEX-N) QuotePress Release - The Globe and Mail
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis - GlobeNewswire
Immix Bio's NXC-201 Achieves 75% Response Rate in AL Amyloidosis Trial, Clinical Data Published in JCO - StockTitan
Immix Biopharma reports strong CAR-T therapy results for AL Amyloidosis By Investing.com - Investing.com South Africa
Immix Biopharma reports strong CAR-T therapy results for AL Amyloidosis - Investing.com
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - GlobeNewswire
Immix Biopharma (IMMX) Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - StreetInsider.com
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Yahoo Finance
Immix Bio's NXC-201 Shows Breakthrough 75% Complete Response Rate in Advanced AL Amyloidosis Trial - StockTitan
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media - GlobeNewswire
Immix Biopharma to Unveil Breakthrough CAR-T Therapy Data for AL Amyloidosis Treatment - StockTitan
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Immix Bio's NXC-201 Achieves 75% Response Rate in Hard-to-Treat Blood Cancer Trial | IMMX Stock News - StockTitan
Immix Biopharma Presents Positive NXC-201 Clinical Data at - GlobeNewswire
Private Advisor Group LLC Has $51,000 Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Renaissance Technologies LLC Decreases Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201 - CGTLive™
Immix BiopharmaUS CAR-T trial progresses to dose expansion - Smartkarma
H.C. Wainwright confident in Immix stock growth with progress in NEXICART-2 CAR-T trial - Investing.com
Immix Biopharma’s (IMMX) “Buy” Rating Reiterated at HC Wainwright - Defense World
XTX Topco Ltd Sells 34,534 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort - GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 - StockTitan
Immix Biopharma stock hits 52-week low at $1.51 amid market challenges - Investing.com Australia
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
Immix Biopharma stock hits 52-week low at $1.74 amid market challenges - Investing.com Australia
Immix Biopharma Announces Dr. Raymond Comenzo, - GlobeNewswire
Immix Biopharma gains AL Amyloidosis expert for advisory board - Investing.com
Immix Biopharma gains AL Amyloidosis expert for advisory board By Investing.com - Investing.com Australia
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board - StockTitan
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update - MarketBeat
It would be worthwhile to take a closer look at Immix Biopharma Inc (IMMX) - US Post News
Its Stock Has Paid Off Big Time For Immix Biopharma Inc - SETE News
The Attractiveness of Investing In Immix Biopharma Inc (IMMX) is Growing - Knox Daily
Immix Biopharma Independent Director Acquires 2.6% More Stock - Yahoo Finance UK
Insider Spends US$52k Buying More Shares In Immix Biopharma - Simply Wall St
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy - Investing.com
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy By Investing.com - Investing.com Canada
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - GlobeNewswire
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immix Biopharma Inc-Aktie (IMMX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hsu Jason | Director |
Aug 22 '24 |
Buy |
2.25 |
8,100 |
18,233 |
845,300 |
| Ng Carey | Director |
Aug 16 '24 |
Buy |
1.86 |
10,000 |
18,600 |
20,000 |
| Hsu Jason | Director |
Jul 24 '24 |
Buy |
2.15 |
6,000 |
12,877 |
822,200 |
| Hsu Jason | Director |
Jul 18 '24 |
Buy |
2.07 |
3,200 |
6,639 |
816,200 |
| Rachman Ilya M | CEO and Chairman |
Jun 07 '24 |
Buy |
2.13 |
2,600 |
5,538 |
1,136,259 |
| Morris Gabriel S | CFO |
Jun 07 '24 |
Buy |
2.12 |
2,500 |
5,298 |
285,834 |
| Morris Gabriel S | CFO |
Jun 04 '24 |
Buy |
1.81 |
3,300 |
5,973 |
283,334 |
| Rachman Ilya M | CEO and Chairman |
Jun 04 '24 |
Buy |
1.81 |
3,300 |
5,970 |
1,133,659 |
| Morris Gabriel S | CFO |
May 14 '24 |
Buy |
2.23 |
4,500 |
10,042 |
85,816 |
| Rachman Ilya M | CEO and Chairman |
May 14 '24 |
Buy |
2.25 |
4,300 |
9,660 |
912,000 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):